Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: The PHEX gene and fibroblast growth factor (FGF)-23 were identified as responsible genes for XLH and ADHR, respectively. In addition, FGF-23 was cloned as a gene abundantly expressed in a responsible tumor for TIO and was shown to reproduce almost all characteristics of TIO when overexpressed in mice. Furthermore, FGF-23 was proteolytically processed between Arg(179) and Ser(180), and all mutations found in ADHR existed in this proteolytic consensus site. Mutant FGF-23 proteins were resistant to the processing and seem to have somehow increased biological activity. There is not yet enough evidence that FGF-23 is phosphatonin, and the relation between PHEX and FGF-23 is unclear. SUMMARY: FGF-23 plays important roles in the development of hypophosphatemic diseases. These findings will certainly contribute to the development of new diagnostic and therapeutic maneuvers for hypophosphatemic diseases.
|
Authors | Seiji Fukumoto, Takeyoshi Yamashita |
Journal | Current opinion in nephrology and hypertension
(Curr Opin Nephrol Hypertens)
Vol. 11
Issue 4
Pg. 385-9
(Jul 2002)
ISSN: 1062-4821 [Print] England |
PMID | 12105387
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- FGF23 protein, human
- Fgf23 protein, mouse
- Phosphates
- Fibroblast Growth Factors
- Fibroblast Growth Factor-23
|
Topics |
- Animals
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors
(metabolism)
- Humans
- Neoplasms
(complications)
- Osteomalacia
(etiology)
- Phosphates
(urine)
|